Dr. Tseng on the Goal of the TARPSWG Analysis in Retroperitoneal Sarcoma

October 27, 2020
William W. Tseng, MD

Partner | Cancer Centers | <b>USC Norris</b>

William W. Tseng, MD, discusses the goals of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

William W. Tseng, MD, an associate professor of Clinical Surgery and a sarcoma surgeon with Keck Medicine of the University of Southern California, discusses the goals of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) analysis in retroperitoneal sarcoma (RPS).

The exploratory TARPSWG analysis was a retrospective study, says Tseng; however, a prospective study is being planned in the near future. One goal of this research was to get as many sarcoma referral centers as possible to participate, adds Tseng. However, the primary goal of the study was to determine whether neoadjuvant systemic therapy is beneficial in patients with RPS.

Prior to surgery, patients were given systemic therapy, with investigators calculating how many achieved a complete response, partial response, or progressive disease. The goal was to have these data quantitated, concludes Tseng.